Investing in healthspan: the business of preventing disease

A new milestone in a business already taking shape

On October 15, the European Medicines Agency's human medicines committee recommended Foundayo, Lilly's oral orforglipron, for weight management and type 2 diabetes. The opinion was published October 16. It brings a potentially important new form of treatment closer to European patients. As of this review on October 19, the cited record is a positive recommendation; the European Commission's authorization decision remains a separate step.

For investors interested in healthier lives, metabolic medicine provides a concrete place to start. There are identifiable products, clinical endpoints, manufacturers and paying customers. This report examines two accessible companies—Eli Lilly, traded as LLY, and Novo Nordisk's U.S. ADR, NVO—and the evidence needed to turn that exposure into an investment judgment. It is a focused starting map, not an exhaustive longevity portfolio.

Source: EMA Foundayo positive opinionSource: Lilly second-quarter 2026 resultsSource: Novo Nordisk second-quarter 2026 financial report

What qualifies as healthspan evidence?

Here, healthspan means the period of life spent in good health. Our investment framework starts with reducing the burden of specific disease. Strong evidence connects a treatment to fewer serious events or improved function in a defined population. Weight, glucose and other measurements can be useful, but the endpoint and the people studied determine what a result establishes.

A historical example is the FDA's March 8, 2024 cardiovascular indication for Wegovy injection. In the trial supporting that decision, major cardiovascular events occurred in 6.5% of treated participants and 8.0% of placebo participants. The population had cardiovascular disease plus obesity or overweight. The difference between those rounded event proportions is 1.5 percentage points over the study period; it is not an annual rate or a result for every patient.

That is meaningful disease-outcome evidence. It does not establish that either company has a general anti-aging treatment, and the result cannot be transferred to a different drug or formulation. We assign no percentage of company revenue to 'longevity.'

Source: FDA: Wegovy cardiovascular indication

Lilly: an expanding product business

Lilly reported Q2 2026 revenue of $22.974 billion, including $9.943 billion for Mounjaro, $4.928 billion for Zepbound and $98 million for Foundayo. Adding the first two gives $14.871 billion, or approximately 64.7% of total quarterly revenue. These are disclosed product sales and our arithmetic, not an estimate of revenue generated by longer life.

The contrast in scale matters: Foundayo contributed about 0.43% of that quarter's revenue. Its European milestone adds a development to watch, while the larger existing franchise still determines much of the near-term business. Q2 ended June 30; these figures are a dated baseline, not an estimate of October sales.

For an investor, the useful sequence is access, sustained use and net revenue. A convenient treatment may expand the pool of people willing to start or continue therapy. The economic benefit depends on actual adoption, how much the manufacturer receives and the cost of serving that demand.

Source: Lilly second-quarter 2026 results

Novo Nordisk: separate operating progress from accounting effects

Novo reported Q2 net sales of DKK 78.488 billion. Its reported operating profit was DKK 27.061 billion, while adjusted operating profit was DKK 33.389 billion. Dividing each by quarterly sales produces margins of approximately 34.5% and 42.5%, respectively. The roughly 8.1-percentage-point gap deserves attention before comparing companies.

The company's adjustments exclude specified rebate provision effects and non-cash pipeline impairments. Reported and adjusted results answer different questions. Keep both visible, and retain DKK rather than casually comparing the revenue number with Lilly's dollar figure. We make no currency conversion or cross-company margin ranking here.

Owning both companies diversifies individual product and execution risk but leaves substantial exposure to common issues: competition in metabolic medicine, payer decisions and the price that patients or insurers will support. Two tickers alone do not create a broad healthspan portfolio.

Source: Novo Nordisk second-quarter 2026 financial report

The commercial checkpoints after a regulatory headline

EMA describes Foundayo as a once-daily tablet that can be taken with or without food. Its explanation also makes the remaining commercial sequence explicit: the Commission decides on EU authorization, then individual member states address pricing and reimbursement. A positive opinion therefore provides a new milestone to track; it supplies neither a launch-sales figure nor a reimbursement price.

Our comparison uses three checkpoints. Clinical: what endpoint improved, for whom, and with what tolerability? Access: where can eligible patients obtain treatment and who pays? Economics: do repeat prescriptions, net prices and production costs support attractive cash generation? This sequence helps investors identify which piece of evidence a fresh announcement actually changes.

The strongest counterargument to buying either stock solely for this theme is valuation. A company can deliver useful medicine and growing sales while its shares disappoint if expectations were already higher. This report maps business exposure; it does not establish a fair value or a buy price.

Source: EMA: oral GLP-1 and the path to patient access

What to watch next

For Lilly, track the Commission decision and subsequent country-level access terms, followed by disclosed Foundayo sales in later quarterly reports. For Novo, compare future reported and adjusted figures on the same definitions, and examine whether growth in treatment volumes translates into attractive economics. For both, disease-outcome evidence, discontinuation and tolerability data matter alongside commercial scale.

Our conclusion is that LLY and NVO deserve a place on an evidence-based healthspan research list. Their existing businesses make the theme measurable. A complete investment decision still requires a valuation, current financial statements, balance-sheet review and an assessment of competing products.

All evidence was retrieved October 19, 2026. Financial observations are for Q2 2026; the FDA cardiovascular example is explicitly historical. No share-price target, treatment recommendation, universal lifespan claim or invented thematic revenue allocation is included. AI-assisted research and writing with source and arithmetic review. Educational investment analysis; individual treatment decisions belong with qualified clinicians.

Source: Lilly second-quarter 2026 resultsSource: Novo Nordisk second-quarter 2026 financial reportSource: FDA: Wegovy cardiovascular indicationSource: EMA Foundayo positive opinion